Pharmaceuticals & the Profit Model

What changes when healing becomes a business, and how to read a drug’s claims.

A pharmaceutical company is neither a demon nor a friend. It is a business: a publicly traded corporation with a legal duty to its shareholders to make as much money as it lawfully can. Hold that single fact in mind, and almost everything else about the industry, the patterns that look baffling, wasteful, or sinister, snaps into focus as the predictable behaviour of a profit-maximising entity responding rationally to its incentives. This page is about those incentives, in detail, because once you can see the economic machinery behind a drug, a study, or an advertisement, you become very hard to mislead, and you can take the genuine, often life-saving value the industry produces while declining the parts designed to separate you from your money or your judgement. This is the incentive-literacy that the Science section was preparing you for, now applied where the stakes are highest.

To be clear from the outset, the pharmaceutical industry has produced some of the greatest lifesavers in human history: the antibiotics, vaccines, insulin, and cancer therapies celebrated in The Role of Modern Medicine. Most people who work in it genuinely want to help the sick. Nothing here is an argument against taking medication you need, and the failure mode of reading a page like this and then refusing a genuinely necessary drug is as dangerous as blind compliance. The system that produces these genuine goods runs on incentives that are not aligned with your long-term health, and understanding exactly how lets you be a far smarter consumer of what it offers. This is the system’s nature, so don’t be surprised when it acts in accordance with it. 

I. How the Money Works

The engine of the whole industry is the patent. When a company develops a new drug, it receives roughly twenty years of patent protection, a temporary monopoly during which no one else may sell that molecule. This is not inherently sinister. Developing a new drug is expensive and risky; most candidates fail, and without a period of protected, monopoly-priced sales to recoup that investment and fund the next round, the risky research might not happen at all. The monopoly is the reward that pays for the discovery.

However, that same patent system creates the single most important pressure in the industry. When a drug’s patent expires, generic manufacturers flood in, and the price collapses; this so-called “patent cliff” can wipe out 80 to 90% of a product’s revenue within months. From the company’s point of view, every blockbuster drug is therefore a melting asset with a hard expiry date, and the entire commercial game becomes a race to maximise revenue before the cliff and to delay the cliff for as long as possible. Once you see that pressure, the industry’s most criticised behaviours stop looking like mysteries and start looking like obvious moves.

II. What the Incentives Produce

Variations over breakthroughs: Genuinely novel drugs, the pioneering treatments for unmet needs, are risky and expensive to develop and often fail. Slight variations on existing, already-proven drugs, the so-called “me-too” drugs, are far cheaper and safer to develop and can capture a share of a proven market. Researchers have found it is far more profitable to extend monopolies on existing medicines and develop variants of them than to undertake the riskier research needed to develop genuinely new medicines. The predictable result is an industry that produces a great many minor variations and comparatively few true breakthroughs. Tellingly, a large share of the genuinely innovative drugs, by one economist’s estimate around 75% of the most innovative new drugs, trace their origins to taxpayer-funded research through bodies like the National Institutes of Health, with the private industry’s own spending skewed toward lower-risk variations and the marketing of them. 

Extending the monopoly by any means available: Because the patent cliff is so costly, companies invest enormous effort in pushing it back, a practice known as “evergreening” or lifecycle management. The tactics are well documented: patenting trivial modifications (a once-daily version of a twice-daily pill, a new coating, a slightly different formulation) to claim fresh patents on an old drug; building “patent thickets” of dozens of overlapping patents to make generic competition legally treacherous (the cancer drug Revlimid accumulated 52 additional patents after its original approval); “product-hopping” patients onto a barely-changed new version just before the old one goes generic; and “pay-for-delay” deals that pay generic manufacturers to stay out of the market. Some of these modifications offer real benefit; many are, in the words of the academic literature, secondary patents of limited to no inventiveness whose effect is to delay generic competition and keep prices high. The point is not that every reformulation is a scam, but that the incentive is to extend the monopoly, whether or not doing so helps you, and you should know which one you are looking at. 

Marketing over research: The industry justifies high prices by pointing to its research costs, but the spending tells a different story. Analyses have found that nearly two-thirds of the hundred biggest pharmaceutical corporations spend at least twice as much on marketing and sales as they do on research and development, and many spend five or ten times as much. That marketing takes two main forms: direct-to-consumer advertising (legal only in the United States and New Zealand, which is why those drug advertisements feel inescapable there and are absent elsewhere), and direct payments and inducements to the doctors who prescribe. The latter has repeatedly crossed into illegality: companies have been penalised for plying physicians with, in the words of one case, free golf, massages, and junkets to resorts to encourage prescribing. The goal of all of it is the goal of any marketing, to sell more products, which is not the same goal as your health.

Selling sickness: A cured patient is a lost customer; a patient managing a chronic condition with a daily pill for forty years is an annuity. This does not mean cures are suppressed, but it does mean the economic wind blows steadily toward lifelong symptom management over resolution, and toward expanding the definition of disease so that more people qualify for treatment. The academic literature notes plainly that medicalising conditions that are neither life-threatening nor debilitating can be far more profitable than developing urgently needed new medicines: lowering the threshold for “high” cholesterol or blood pressure, turning ordinary variations of mood, attention, or sexuality into diagnosable conditions, inventing syndromes to fit drugs looking for a market. This is “disease-mongering,” and the antidote is the question the manual keeps returning to: is this treating a genuine problem at its root, or managing a symptom, or selling me a condition I did not know I had? 

III. When the Incentive Turns Deadly

So far, these are the ordinary distortions of a profit-driven system, costly and cynical but not, in themselves, lethal. But the same incentive structure, taken to its logical end and combined with weak enough deterrence, produces something far darker: cases where companies have concealed the harms of their products and kept selling them, and where the profit from doing so exceeded the eventual penalty. The clearest and most thoroughly documented case in modern history is the opioid crisis.

The story of Purdue Pharma and OxyContin is fact, documented in court records, government settlements, and the company’s own internal documents. Purdue, owned by the Sackler family, marketed the powerful opioid OxyContin from the late 1990s with aggressive and false claims that it carried a low risk of addiction. As evidence of widespread addiction and overdose mounted, internal documents later revealed that executives knew the drug was being abused and continued aggressive marketing, even discussing strategies to “blame the addicts” rather than the product. The company pleaded guilty to federal charges in 2007 and then, extraordinarily, continued the conduct. Over the period in which OxyContin was widely prescribed, more than 300,000 people died from prescription-opioid overdoses, with hundreds of thousands more deaths as addiction transitioned to heroin and fentanyl. The eventual reckoning saw Purdue dissolved and a settlement of around $7.4 billion from Purdue and the Sackler family, against the roughly $10.7 billion the Sacklers had extracted from the company over the preceding decade. This is the case that proves the principle in its starkest form: a product known by its maker to be killing people, kept on the market because it was extraordinarily profitable to do so. 

The opioid catastrophe is the extreme, but the underlying logic, that harms can be concealed or downplayed when disclosure would cost sales, recurs across the industry’s history, from the suppression of unfavourable safety data to the marketing of drugs for unapproved and unsafe uses. Which raises the obvious question: why don’t the penalties stop it?

IV. Why the Fines Do Not Stop It

Here is the structural heart of the matter, and it is more damning and more useful to understand than any story about individual villains. The reason misconduct persists is that, for a large and profitable enough drug, the financial penalty for getting caught is often smaller than the profit from the misconduct. When that is true, a purely rational profit-maximising entity will treat the fine not as a deterrent but as a cost of doing business, a line item, a tax on a profitable activity, to be paid and absorbed while the activity continues.

When the US Department of Justice levied a record $3 billion fine on GlaxoSmithKline in 2012, its own official noted that “for far too long, we have heard that the pharmaceutical industry views these settlements merely as the cost of doing business.” And the numbers bear the complaint out. That record $3 billion GSK fine amounted to just 11% of the revenue associated with the drugs involved, and even the largest settlements rarely dent the profits of the drugs at issue. Stepping back to the whole industry, one analysis found that between 1991 and 2021, drug companies paid $62.3 billion in penalties across at least 482 cases, a sum amounting to a small percentage of the $1.9 trillion in net income earned by just the 35 largest companies over a portion of that period, and a study in JAMA found that 85% of the large pharmaceutical companies sampled had been financially penalised for illegal activity between 2003 and 2016, making misconduct less an aberration than a near-universal feature. When penalties are this routine and this small relative to the gains, they function exactly as a cost of doing business, and the deterrent effect that fines are supposed to provide largely evaporates. The problem, seen clearly, is not that pharmaceutical executives are unusually evil people; it is that the incentive structure makes certain harms profitable even after they are punished, and a system that rewards a behaviour will reliably produce it. That is a far more sobering diagnosis than villainy, because it will keep producing the same result until the incentives themselves change. 

V. Holding the Balance

It would be easy to finish the section above and conclude that the whole enterprise is rotten and that the sensible response is to refuse its products. Everything above is true, and so is everything in The Role of Modern Medicine: this same industry produces antibiotics that save you from sepsis, vaccines that have prevented untold deaths, insulin that keeps diabetics alive, and cancer drugs that genuinely extend lives. The industry is, exactly as the section’s introduction put it, full of people who want to make a difference, operating inside a structure funded by interests that mostly do not, and producing genuine miracles and cynical exploitation through the very same machinery.

The intelligent response is therefore not rejection and not trust, but literacy: the ability to tell, in a given case, which you are looking at. The same drug company that sold you a life-saving antibiotic may, the same year, be running a disease-mongering campaign for a me-too drug you do not need; recognising the difference is the skill. And critically, none of this scrutiny falls on the people you actually deal with, your doctor, your pharmacist, the nurse, who are not the architects of these incentives and are mostly doing their best inside them. The target of the scepticism is the system and its claims, never the person trying to help you.

VI. Reading a Drug’s Claims

So how do you actually apply this in practice when a drug is recommended, advertised, or in the headlines? A handful of questions, drawn from the Scientific Methodology Cheat Sheet and pointed specifically at medication, give you most of the protection:

• Absolute or relative risk? This is the most important and most exploited distinction in all of drug marketing. “Cuts your risk of a heart attack by 50%” sounds dramatic, but if it lowers your risk from 2 in 100 to 1 in 100, the absolute benefit is one percentage point, and 99 of every 100 people who take it for that reason get no benefit at all. Marketing almost always quotes the impressive relative figure; the absolute figure is what tells you whether it matters for you. Always ask for it.
• What is the NNT? The “number needed to treat”, how many people must take the drug for one person to benefit, turns the abstract into the concrete. An NNT of 5 is a genuinely effective drug; an NNT of 100 means ninety-nine people take it (and risk its side effects) for every one who is helped. Ask it, and ask the matching “number needed to harm.”
• Who funded the study, and what was it compared against? Industry-funded trials more often favour the sponsor’s drug, as the History of Science section showed for other industries. And a drug shown to beat a placebo has not been shown to beat the cheaper, older, or non-drug alternative; ask what the comparator was.
• Is this a genuine advance or an evergreened variant? A “new” drug may be a true breakthrough or a barely-modified version of an old one, repatented as the original goes generic. The generic is usually a fraction of the price for the same benefit; it is always worth asking whether one exists.
• Is this treating a cause or managing a symptom, and is it a real condition? The manual’s recurring question. A symptom-suppressant may be exactly right in a crisis, but ask what the underlying cause is, whether it can be addressed upstream, and whether the “condition” being treated is a genuine problem or a marketed one.
• What are the non-drug alternatives? For a great many chronic conditions, the upstream levers of Part I and Part II are genuine alternatives or complements to medication, and a profit-driven system has no incentive to mention them. You will usually have to raise them yourself.

VII. Pulling It Together

The pharmaceutical industry is a profit-maximising business that happens to produce some of the most valuable things in the world alongside some of the most cynical, through a single machine driven by patents, monopolies, and the relentless pressure to sell. Understanding that machine, the patent cliff, the me-too drugs, the evergreening, the marketing that dwarfs research, the disease-mongering, and the documented cases where profit was allowed to outweigh human lives because the fines were cheaper than stopping, is not a reason to fear or reject medicine. It is what lets you use medicine well: gratefully and fully for the genuine miracles, sceptically and selectively for the rest, and always with the questions that tell the two apart.

The moment a person grasps all of this and loses faith in the pharmaceutical industry, they become the perfect customer for the industry that sells itself as the alternative, the supplement, wellness, and “natural” health world, which runs, as the next page shows, on remarkably similar incentives in gentler clothing. The line that protects you is the same in both directions: not establishment versus alternative, but rigorous versus lazy. We turn that lens on the alternatives in Alternative & Integrative Medicine.

VIII. Cross-Links

• Medical & Pharmaceutical Industries for the section overview
• The Role of Modern Medicine for the genuine miracles the same industry produces
• Diagnostics & Systems Navigation for working with the system well
• Alternative & Integrative Medicine for the same lens turned on the wellness industry
• Medical Ethics, Misinformation & Personal Choice for consent, trust, and autonomy
• Resources for the reading list